Clinical Trial Update: Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy [Phase 2]

View source ↗

Summary

A Phase 2 efficacy and safety study of Ammonul in patients with grade 3 or 4 hepatic encephalopathy was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Encephalopathy

Drugs mentioned

• Ammonul (sodium phenylacetate and sodium benzoate)

Snippet

Sponsor: Amgen | Conditions: Hepatic Encephalopathy | Phase 2 | Status: TERMINATED | Results posted: 2016-03-31